Swiss National Bank Acquires 2,100 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Swiss National Bank raised its holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX – Get Rating) by 2.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 90,300 shares of the biopharmaceutical company’s stock after purchasing an additional 2,100 shares during the quarter. Swiss National Bank’s holdings in Celldex Therapeutics were worth $4,025,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently bought and sold shares of CLDX. Wellington Management Group LLP grew its stake in Celldex Therapeutics by 61.5% in the 1st quarter. Wellington Management Group LLP now owns 3,529,840 shares of the biopharmaceutical company’s stock valued at $120,227,000 after purchasing an additional 1,343,864 shares during the period. Bellevue Group AG grew its stake in shares of Celldex Therapeutics by 94.6% during the 3rd quarter. Bellevue Group AG now owns 1,800,000 shares of the biopharmaceutical company’s stock worth $50,598,000 after acquiring an additional 875,000 shares during the period. Marshall Wace LLP grew its stake in shares of Celldex Therapeutics by 3,159.9% during the 3rd quarter. Marshall Wace LLP now owns 652,721 shares of the biopharmaceutical company’s stock worth $18,348,000 after acquiring an additional 632,698 shares during the period. State Street Corp grew its stake in shares of Celldex Therapeutics by 20.4% during the 2nd quarter. State Street Corp now owns 3,228,852 shares of the biopharmaceutical company’s stock worth $87,050,000 after acquiring an additional 546,124 shares during the period. Finally, Eventide Asset Management LLC grew its stake in shares of Celldex Therapeutics by 23.9% during the 3rd quarter. Eventide Asset Management LLC now owns 1,791,800 shares of the biopharmaceutical company’s stock worth $50,367,000 after acquiring an additional 346,100 shares during the period.

Analysts Set New Price Targets

Several research firms have recently weighed in on CLDX. Cantor Fitzgerald cut their price target on Celldex Therapeutics from $55.00 to $54.00 in a research note on Friday, May 5th. HC Wainwright restated a “buy” rating and issued a $73.00 target price on shares of Celldex Therapeutics in a research note on Wednesday, March 1st. Finally, StockNews.com began coverage on Celldex Therapeutics in a research note on Thursday. They issued a “sell” rating for the company.

Celldex Therapeutics Stock Up 5.1 %

NASDAQ:CLDX opened at $32.89 on Friday. The business’s 50-day moving average price is $34.72 and its two-hundred day moving average price is $39.15. Celldex Therapeutics, Inc. has a twelve month low of $19.85 and a twelve month high of $48.40. The stock has a market cap of $1.55 billion, a P/E ratio of -13.05 and a beta of 2.10.

Celldex Therapeutics (NASDAQ:CLDX – Get Rating) last released its quarterly earnings results on Tuesday, February 28th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.03. The firm had revenue of $1.61 million for the quarter, compared to analysts’ expectations of $0.16 million. Celldex Therapeutics had a negative return on equity of 32.84% and a negative net margin of 3,766.22%. On average, equities research analysts expect that Celldex Therapeutics, Inc. will post -2.64 EPS for the current fiscal year.

Celldex Therapeutics Company Profile

(Get Rating)

Celldex Therapeutics, Inc engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379.